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Abstract Over the last decade, pioneering liver-directed gene
therapy trials for haemophilia B have achieved sustained clin-
ical improvement after a single systemic injection of adeno-
associated virus (AAV) derived vectors encoding the human
factor IX cDNA. These trials demonstrate the potential of
AAV technology to provide long-lasting clinical benefit in
the treatment of monogenic liver disorders. Indeed, with more
than ten ongoing or planned clinical trials for haemophilia A
and B and dozens of trials planned for other inherited genetic/
metabolic liver diseases, clinical translation is expanding rap-
idly. Gene therapy is likely to become an option for routine
care of a subset of severe inherited genetic/metabolic liver
diseases in the relatively near term. In this review, we aim to
summarise the milestones in the development of gene therapy,
present the different vector tools and their clinical applications
for liver-directed gene therapy. AAV-derived vectors are
emerging as the leading candidates for clinical translation of
gene delivery to the liver. Therefore, we focus on clinical
applications of AAV vectors in providing the most recent up-
date on clinical outcomes of completed and ongoing gene
therapy trials and comment on the current challenges that the
field is facing for large-scale clinical translation. There is
clearly an urgent need for more efficient therapies in many
severe monogenic liver disorders, which will require careful
risk-benefit analysis for each indication, especially in
paediatrics.
Introduction
The liver is a key-regulator of multiple complex metabolic
pathways and the hepatocyte is a primary cell type affected
in numerous inherited genetic/metabolic diseases (Clayton
2002). Despite a wide range of disease-specific conventional
therapies, liver replacement therapies remain a valid strategy
and even a potential cure for many monogenic liver disorders
due to the ability to restore the defective pathway (Sokal
2006). Liver replacement options include whole or partial or-
gan (Spada et al 2009), or hepatocytes transplantation
(Dhawan et al 2006). The shortage of donors, the associated
mortality/morbidity and need for immunosuppression, how-
ever, often limit this option to severely affected patients and
those aged more than 3 months or weighing greater than 5 kg
(Haberle et al 2012). In the past decade, liver-directed gene
therapy has emerged as a promising alternative to transplan-
tation in monogenic liver disorders.
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Overview of gene therapy development: reaching
maturity
Gene therapy, by providing additional functional gene copies,
has been considered for decades as an attractive option for
treatment of monogenic disorders (Wirth et al 2013).
According to the Gartner hype cycle, a graphical representation
depicting the maturity of novel technologies, gene therapy
reached its Bpeak of inflated expectation^ in the mid-1990s
which was paralleled by a rapid rise in clinical trial activity
and the publication of early proof-of-concept studies for genetic
and acquired conditions such as adenosine-deaminase deficien-
cy (ADA-SCID) (Blaese et al 1995; Bordignon et al 1995) and
brain tumours, respectively (Puumalainen et al 1998). This pe-
riod of inflated expectation was critiqued in the Orkin-
Motulsky report commissioned by the National Institute of
Health (Orkin and Motulsky 1995). While acknowledging the
extraordinary promise of gene therapy, the report emphasised
the need for greater focus on gene transfer technology and the
basic science of gene transfer. Soon after, the field plunged into
its Btrough of disillusionment^ following the death of a young
adult, Jesse Gelsinger, in a clinical trial for ornithine
transcarbamylase (OTC) deficiency (Raper et al 2003).
Optimism arising from the subsequent clinical success in the
treatment of X-linked severe combined immunodeficiency
(SCID-X1) (Cavazzana-Calvo et al 2000) was soon dampened
by the occurrence of leukaemia in five out of 20 patients sec-
ondary to insertional mutagenesis (Hacein-Bey-Abina et al,
2003a, b; Fischer et al 2010; Mukherjee and Thrasher 2013),
causing the death of one participant (Mukherjee and Thrasher
2013). Resultant concerns over gene therapy were further
compounded by growing awareness of the challenges imposed
by vector-induced immune responses (Mingozzi and High
2007). Disbelief and doubt followed, leading to a decline in
financial investment (Ledley et al 2014). In parallel, these ad-
verse events motivated researchers to seek a better understand-
ing of the challenges posed by disease pathophysiology and to
develop safer and more efficient vectors. Recent clinical suc-
cesses in various inherited orphan diseases such as Leber’s
congenital amaurosis (Bainbridge et al 2008; Cideciyan et al
2008; Maguire et al 2008), X-linked adrenoleukodystrophy
(Cartier et al 2009), metachromatic leukodystrophy (Biffi et al
2013) and haemophilia B (Nathwani et al 2011) and the first
market authorisation granted by the European Medicines
Agency (EMA) in 2012, to Glybera® for lipoprotein lipase
deficiency (Bryant et al 2013), are driving the field up the
Bslope of enlightenment^ and onto the Bplateau of
productivity .^ As a result of this success, various biotechnology
companies dedicated to gene therapy development have been
created and received substantial financial investment (Cassiday
2014). In parallel, the number of gene therapy-based clinical
trials has risen rapidly in recent years (http://www.abedia.com/
wiley/(accessed 2017 Jan 06); Ginn et al 2013).
Strategies for hepatocyte-directed gene transfer
A growing toolbox is available for gene transfer, which has
been the preferred approach in recent human trials targeting
hepatocytes. Various elements in the choice of transgene ex-
pression cassette design, mode of delivery and the subset of
patients targeted influence the efficacy of gene therapy
(Fig. 1).
Parameters of vector delivery
The mode of transgene delivery is crucial: i) local injection
allows highly selective expression, but in a limited area.
Conversely an intravenous injection allows a broad distribu-
tion balanced by non-specificity. Injections in the hepatic ar-
tery or the portal vein improve the selectivity but require can-
nulation with its associated risks (Fumoto et al 2013).
Peripheral intravenous delivery provides similar transduction
compared to intrahepatic or intraportal routes for AAV vectors
(Sarkar et al 2006; Nathwani et al 2007); ii) higher doses of
vector achieve greater transduction, but may generate more
severe immune responses (Raper et al 2003; Mingozzi and
High 2013).
Host pre-sensitisation or acquired immune responses
The immune response against the vector and/or the transgene
product might preclude the expected therapeutic effect (Jooss
and Chirmule 2003; Zaiss and Muruve 2008; Wold and Toth
2013).
Immune memory of pre-exposure to wild-type viruses can
prevent efficient hepatocyte transduction by pre-existing
neutralising antibodies and might account for differences in
the severity of immune responses observed after systemic in-
jection. Pre-immunisation against the transgene product can
occur when the recombinant transgenic protein has been ad-
ministered. For example, in haemophilia B patients, this can
result in the generation of anti-factor IX antibodies when treat-
ed by recombinant factor IX (Armstrong et al 2014).
Accordingly prior immunisation needs to be carefully consid-
ered in clinical trial enrolment criteria.
Acquired immune responses after systemic gene delivery
are common. Innate immune responses are triggered by anti-
gen presenting cells such as dendritic cells or macrophages
initiating the release of proinflammatory cytokines (interleu-
kins 1 and 6, tumour necrosis factor α (TNFα), type I inter-
feron α and β) via stimulation of Toll-like receptors (TLR).
Specific and long-lasting antigen-specific immune responses
are mediated by B- and T-cells and involve secretion of
neutralising antibodies and CD8+ cytotoxic T lymphocytes,
respectively, regulated by the recruitment of helper and regu-
latory CD4+ T cells. Whatever the viral vector considered,
immune responses share various similarities, and must always
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be carefully considered (Bessis et al 2004; Tang et al 2006;
Annoni et al 2013; Calcedo and Wilson 2013; Basner-
Tschakarjan and Mingozzi 2014).
Design and selection of the gene transfer vector
The transgene expression cassette contains i) a transgene,
which is commonly a cDNA and may be codon-optimised
to achieve higher expression of the transgene product, ii) an
enhancer/promoter, the selection of which determines the lev-
el of transgene expression, cell-type restricted specificity of
expression and also influences the risk of insertional mutagen-
esis, iii) various pre- and/or post-regulatory elements to stabi-
lise transgene mRNA and therefore increase the yield of trans-
gene product, e.g. addition of an intron downstream of the
promoter containing a bacterial replication origin (Lu et al
2017) or the woodchuck hepatitis virus post-transcriptional
regulatory element (WPRE) (Lipshutz et al 2003),
respectively.
Several options are available to deliver the transgene
expression cassette to the target cell/organ
Injection of naked DNA, either as plasmids (Doenecke et al
2010; Oishi et al 2016) or mini-circles (Viecelli et al 2014;
Hou et al 2016; Wu et al 2016), is a simple mode of transgene
delivery which lends itself to local delivery and is relatively
non-immunogenic compared to some viral vector approaches
(Wolff and Budker 2005). Mini-circles are devoid of plasmid
backbone DNA; this may enhance transgene expression by
overcoming heterochromatin formation and avoiding inflam-
mation triggered by bacterial DNA (Mayrhofer et al 2009).
These approaches allow easy production of therapeutic mate-
rial with a good safety profile and capable of eliciting long-
lasting transgene expression in post-mitotic tissues (Wolff and
Budker 2005; Kay et al 2010). These approaches have been
employed in ∼17% of gene therapy trials so far (http://www.
abedia .com/wiley/ (accessed 2017 Jan 06)) . The
hydrodynamic injection technique, developed in small
animal models, consists of injecting DNA plasmids or mini-
circles in a large vehicle volume to flood the liver with
pressurised DNA solution; this disrupts vascular endothelium,
and allows high levels of transgene expression in small or
large animal models (Liu et al 1999). Although hydrodynamic
injections are difficult to translate to humans, intravascular
hydrodynamic procedures with partial catheterisation for
liver-directed gene delivery have shown some success in large
animals (Sendra et al 2016; Yokoo et al 2016). However,
current translatable options of non-viral approaches remain
limited. Therefore viral vectors, acting as Trojan horses to
increase transduction efficiency, are frequently considered.
Non-viral vectors are synthetically produced biological
particles, in which the transgene is encapsulated, or com-
plexed, and released at the target site. Various engineered
nanoparticles exist, e.g. liposomes or/and polymers (Chira
Vector type
(If virus-derived, serotype) 
Dose of vector
Route of administration
VECTOR DELIVERY
 Immune responses against
HOST
Transgene productVector
VECTOR
CONSTRUCT
Promoter Transgene
Regulatory
elements
Fig. 1 The triad to consider for
successful gene therapy
J Inherit Metab Dis
et al 2015). These options have several advantages: easy pro-
duction, no restriction of the transgene size, and a reliable
safety profile. Limitations are the stability of these particles,
cellular uptake and a limited ability to achieve long-lasting
transgene expression (Elsabahy et al 2011). These are there-
fore suboptimal delivery vehicles for liver-directed clinical
trials.
Virus-derived vectors represent an attractive approach based
on their relatively efficient transduction human cells. The main
vectors that have been used in clinical trials are derived from
adenoviruses (21%), retroviruses (excluding lentiviruses)
(19%), adeno-associated viruses (7%) and lentiviruses (6%)
(http://www.abedia.com/wiley/(accessed 2017 Jan 06)).
Retroviral vectors
Gamma-retroviruses such as murine leukaemia viruses
(MLVs) are RNA viruses encoding gag, pol and env genes
flanked by long terminal repeats (LTRs), which carry
enhancers/promoter elements and are required for integration.
After transduction of the target cell, reverse-transcription gen-
erates a double-stranded DNA copy of the proviral genome,
which then integrates in the host genome providing long-term
transgene expression. Gamma-retroviruses are unable to trans-
duce non-dividing cells as the nuclear membrane prevents
retroviral vectors from entering the nucleus (Miller et al
1990). This explains why this vector is more often considered
for ex vivo gene therapy in which cultured target cells are
stimulated to replicate and then transduce. Lentiviruses are a
class of retroviruses, the most widely known of which is
HIV1. Lentiviral vectors are able to transduce dividing and
non-dividing cells, which broadens their application.
Retroviral vectors have relatively large transgene capacities
(7.5 kilobases (kb)) (Verma and Somia 1997). In fact payloads
exceeding 14 kilobases have been packaged into lentiviral
vectors (Counsell et al, 2017).
Clinical applications and limitations: In an early gene ther-
apy trial, a γ-retroviral vector was used in an ex vivo approach
with autologous hepatocytes in five patients with homozygous
familial hypercholesterolemia. This showed a mild improve-
ment of lipid profiles in two patients with a very low rate of
stable engraftment at 4 months after gene therapy (Grossman
et al 1994; Grossman et al 1995). Several limitations emerged
from this trial: i) the need for two invasive procedures, i.e. the
surgical resection of a liver lobe to obtain sufficient primary
hepatocytes for transduction as hepatocytes cannot be expand-
ed in culture and reinjection of transduced hepatocytes into the
portal circulation via a local catheter, with the associated risks
of venous thrombosis, catheter misplacement and haemor-
rhage (Grossman et al 1994; Raper et al 1996). The efficiency
with which hepatocytes were harvested and transduced was
low, 30% and 10% respectively (Grossman et al 1995).
Protocols for lentiviral-mediated gene therapy have improved
with in vitro transduction efficacy reaching 90% in non-
human and human hepatocytes (Nguyen et al 2009).
Hepatocyte transplantation, however, remains relatively inef-
ficient and variable, likely due to poor engraftment, limited
persistence of engrafted hepatocytes and the lack of a prolif-
erative advantage (Gramignoli et al 2015).
Retroviral-mediated in vivo gene therapy was well tolerat-
ed when vector was administered intravenously in
haemophilia A patients, but no significant clinical benefits
were observed (Powell et al 2003). Preclinical studies failed
to accurately predict the therapeutic dose and it was suggested
that retroviral vectors were unable to transduce non-dividing
hepatocytes (Chuah et al 2004). Therefore, alternative viral
vectors, including lentiviral vectors, have been developed for
treatment of hemophilias. Indeed two promising approaches
with lentiviral vectors are in preclinical development: i) sys-
temic lentiviral-mediated liver-restricted gene therapy in a dog
model of haemophilia B, which showed long-term efficacy,
induction of liver tolerogenic properties in stimulating
CD4+CD25+FoxP3+ regulatory T cells and no evidence of
genotoxicity in mice (Cantore et al 2015). The immune toler-
ance is of particular interest for patients with anti-FIX inhibi-
tors, who are currently excluded from gene therapy trials; ii)
ex vivo transduction of haematopoietic stem cells (HSC) in
mice with successful FIX gene expression to target cells of the
erythroid (Chang et al 2008) or the megakaryocyte lineage
(Chen et al 2014). A lentiviral vector is currently in preclinical
development for haemophilia B (Dolgin 2016). Lentiviral
vectors are able to accommodate large transgenes such as
FVIII gene for haemophilia A (Kuether et al 2012).
Lentiviral-mediated liver-directed ex vivo gene therapy has
been successfully reported in a pig model of tyrosinaemia 1
using the selective advantage of Fah+/+ modified hepatocytes
(Hickey et al 2016).
The risk of insertional mutagenesis has been reported with
retroviral vectors (Cavazzana-Calvo et al 2000; Mukherjee
and Thrasher 2013), however, there is evidence that the risk
is lower with lentiviral vectors (Kotterman et al 2015). To
improve safety, self-inactivating (SIN) vectors have been de-
veloped in which LTR enhancer/promoter elements in the U3
region have been deleted (Miyoshi et al 1998; Zufferey et al
1998). This, however, does not completely eliminate the risk
of insertional mutagenesis as heterologous enhancer-promoter
elements still need to be included in vector constructs.
Genotoxicity has been observed after foetal injections of
non-primate and primate SIN-lentiviral vectors (Nowrouzi
et al 2013; Condiotti et al 2014). So far, more than 125 patients
over 14 years have been treated with haematopoietic stem
cells or T cells transduced by lentiviral vectors with no onco-
genic event reported (Cartier et al 2009; Biffi et al 2013;
McGarrity et al 2013; Booth et al 2016). Another approach
relies on the mutation of the integrase protein to generate non-
J Inherit Metab Dis
integrating or integration-deficient lentiviral vectors
(Nightingale et al 2006; Philippe et al 2006; Yanez-Munoz
et al 2006), which have shown long-lasting gene expression
in non-dividing tissues (Apolonia et al 2007; Rahim et al
2009) and phenotype correction in mice with haemophilia B
(Suwanmanee et al 2014).
Adenoviral vectors
Adenoviruses are non-enveloped double-stranded DNA vi-
ruses with a large 36 kb genome and are capable of trans-
ducing dividing and non-dividing cells. In humans, a com-
mon target is epithelial cells of the respiratory or gastroin-
testinal tracts causing mild upper respiratory tract infection,
gastroenteritis, or asymptomatic seroconversion. More than
55 serotypes are described but most vectors are derived from
endemic serotypes 2 and 5 (Piccolo and Brunetti-Pierri
2014). The seroprevalence against the most common sero-
type (Adenovirus 5) is high with neutralising antibodies in
45–80% (Kotterman et al 2015). Adenoviruses elicit a
sustained innate and cytotoxic-mediated immunity, which
leads to the clearance of transduced cells (Tang et al 2006;
Thaci et al 2011). Neither adenoviruses nor adenoviral vec-
tors have been associated with genotoxicity in humans
(Stephen et al 2010). Adenoviral vectors can accommodate
large transgenes, which remain episomal in the transduced
cell but enable a long-lasting transgene expression in quies-
cent or dividing cells. In animal models, adenoviral vectors
exhibit strong liver tropism through interaction with coagu-
lation factor X (Kalyuzhniy et al 2008; Vigant et al 2008;
Waddington et al 2008).
Clinical applications and limitations
In adenoviruses, expression of genes occurs in two early and
late phases. The early phase is mediated by E1-E4 transcrip-
tion units. Proteins encoded by E1 are essential for viral gene
expression and DNA replication. Late gene expression is me-
diated by an internal promoter (Benihoud et al 1999). First-
generation adenoviral vectors have E1 or E1-E3 regions re-
moved and are theoretically replication-defective. However,
these vectors keep a mild Bleaky^ expression of viral genes
and are still able to synthesise some viral proteins, likely due
to E1-like protein in the target cells (Zhang et al 1998; Lozier
et al 1999). Moreover, the immunogenic properties of first-
generation adenoviral vectors cause severe acute innate and
chronic adaptive immune responses in small and large ani-
mal models (Yang et al 1994). To reduce this immune re-
sponse, deletion of transcription units E1/E2/E3, E1/E4/E3,
E1/E2/E3/E4) has been introduced (Alba et al 2005). Only
the last combination achieved a reduction of vector toxicity,
but with a reduced duration of the transgene expression
(Gao et al 1996; Raper et al 1998; Andrews et al 2001). A
second generation (E1- and E4- deleted) adenoviral 5
vector was used for the OTC deficiency trial, in which
Jesse Gelsinger, a young adult with late-onset OTC de-
ficiency enrolled in the highest dose group, died after
developing a fatal acute toxic reaction with fulminant
inflammatory response and multi-organ failure hours af-
ter the injection of the vector (Raper et al 2003). It has
been hypothesised that this was caused by an innate im-
mune response with a cytokine storm triggered by anti-
gen presenting cells against capsid proteins (Raper et al
2003). The reason for severity of this immune response
remains unclear as another patient injected with the same
dose exhibited only mild flu-like symptoms. A genetic
predisposition or an immune memory response caused
by pre-exposure to adenoviruses might partly explain this
discrepancy (Wilson 2009). In this trial, safety issues
were surprisingly not dose-related and had not been pre-
dicted to this extent by animal studies (Raper et al 2002).
Furthermore, no significant clinical benefit was observed
(Raper et al 2002).
To limit this immune response, Bgutless^ or helper-
dependent adenoviral vectors (HD-Ad) have been designed
by deletion of all coding regions except the ITRs and the
packaging signal (Ψ) required for the encapsidation of the
adenoviral genome, which have been replaced by the trans-
gene cassette and stuffer DNA (Alba et al 2005). This new
generation of vectors have shown an improved safety profile,
exhibiting a reduced acute innate immune response and an
absence of chronic toxicity. In first-generation adenoviral vec-
tors, the Bleaky^ expression of the remaining viral genes have
a direct cytotoxic effect and triggers an adaptive cellular im-
mune response directed against the transduced cell, which in
turn results in transient transgene expression and chronic tox-
icity (Brunetti-Pierri and Ng 2011). As HD-Ad do not contain
any viral genes, this late toxicity is not observed, which allows
a long-term transgene expression as observed in small (Kim
et al 2001; Toietta et al 2005) and large animal models (Morral
et al 1999; Brunetti-Pierri et al 2006). This has allowed suc-
cessful long-term phenotypic correction of various liver
monogenic disorders (Brunetti-Pierri and Ng 2011), among
which haemophilia A (Reddy et al 2002; Hu et al 2011),
haemophilia B (Ehrhardt and Kay 2002), OTC deficiency
(Mian and Lee 2002), glycogen storage disease 1A (Koeberl
et al 2007), Criggler-Najjar syndrome (Schmitt et al 2014),
primary hyperoxaluria type 1 (Castello et al 2016), acute in-
termittent porphyria (Unzu et al 2013), phenylketonuria
(Cerreto et al 2012), familial hypercholesterolaemia caused
by mutations in the LDLR (Nomura et al 2004) and ApoE
genes (Belalcazar et al 2003) in rodents, haemophilia A
(Brown et al 2004; McCormack et al 2006) and B (Ehrhardt
et al 2003; Brunetti-Pierri et al 2005), glycogen storage dis-
ease type 1 (Crane et al 2012) in dogs, and haemophilia A and
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B and Pompe disease (Rastall et al 2016) in non human
primates.
However, the acute innate immune response directed against
capsid proteins is not abolished in HD-Ad vectors (Muruve et al
2004). For both first-generation and helper-dependent adenoviral
vectors, this acute immune response is dose-dependent and can
be lethal at high doses in non human primates (Morral et al 2002;
Brunetti-Pierri et al 2004). Differences in the severity of the
immune response between species have emerged due to variable
interactions between blood cells and hepatic microarchitecture
such as size of liver sinusoidal fenestration (Piccolo and
Brunetti-Pierri 2014). The activation of this innate immunity is
multifactorial. Adenoviral particles can trigger the immune re-
sponse by binding to Toll-like receptors (TLR2, TLR9) at the
surface of antigen presenting cells, and/or activate the comple-
ment cascade in the bloodstream (Kiang et al 2006; Zhu et al
2007). Kupffer cells recognise the adenoviral capsid either via
antibody-mediated opsonisation or in binding complement fac-
tors. Kupffer cells develop a pro-inflammatory state with necrotic
death, which further disseminate the immune response
(Schiedner et al 2003).
In vivo HD-Ad mediated gene therapy has been performed
in one patient in a phase I trial for haemophilia A. After a
single intravenous low-dose injection, the patient developed
flu-like symptoms with transient fever, chills, back pain, head-
ache and transient biological abnormalities including throm-
bocytopenia, laboratory features of disseminated intravascular
coagulopathy, increase in interleukin 6 levels, and elevated
liver transaminase levels peaking at 7 days (marked as grade
3 liver toxicity) (Chuah et al 2004; White and Monahan 2005;
Chandler and Venditti 2016). The patient expressed 1% FVIII
for some months but the trial was halted for safety reason
although biological abnormalities came back to normal within
19 days. Unfortunately, this trial has not been published in a
peer-reviewed format and few details are available (Piccolo
and Brunetti-Pierri 2014). The cause of these symptoms re-
mains unclear although, as supposed for the OTC trial involv-
ing Jesse Gelsinger, the innate immune response against the
adenoviral capsid and its subsequent release of cytokines has
been suspected (Chuah et al 2004). Contamination by an ad-
enoviral helper virus remains a possible explanation (Chuah
et al 2004).
Despite limited application for liver monogenic disorders,
adenoviral vectors have been successfully used for oncolytic
virotherapy (Rosewell Shaw and Suzuki 2016) and vaccina-
tion (Majhen et al 2014), which exploits adenoviral
immunogenicity.
Adeno-associated viral vectors
Adeno-associated viruses (AAV) are non-enveloped, single-
stranded DNAviruses that belong to the Dependovirus genus
and the Parvoviridae family. Initially identified as a contam-
inant of an adenoviral preparation (Atchison et al 1965), the
virus was later shown to require co-infection with a helper
virus to replicate. In the absence of helper virus, AAV can
enter target cells and establish latent infection through geno-
mic integration and/or formation of episomes. AAV is widely
considered non-pathogenic and has yet to be definitively
linked to disease causation. AAVs can transduce dividing
and non-dividing cells. The seroprevalence against the most
common serotype AAV2 is 40–60% (Louis Jeune et al 2013).
AAV virions consist of an icosahedral capsid of approximately
22 nm in diameter enclosing a 4.7 kb single-stranded genome.
The genome is flanked by two 145 nucleotide inverted termi-
nal repeats (ITRs) containing all of the necessary cis-acting
functions for proviral rescue, genome replication and packag-
ing. The viral genome encodes 4 Rep proteins required for
proviral rescue and genome replication, and three viral pro-
teins VP1, VP2 and VP3, which assemble to form the capsid
(Fig. 2A) (Samulski and Muzyczka 2014). Some, but not all,
AAV capsid serotypes (Earley et al 2017) require expression
of an assembly-activating protein (AAP) encoded by an alter-
native reading frame of the Cap gene and providing scaffold-
ing activity (Naumer et al 2012). Numerous AAV serotypes
have been isolated from humans, non-human primates and
other species, with the viral capsid determining species and
target cell tropism through interaction with a diversity of cell
surface receptors/co-receptors and intracellular trafficking
pathways that remain incompletely understood. A multi-
serotype AAV receptor has been recently identified (Pillay
et al 2016), but its precise role in uptake and trafficking has
yet to be elucidated (Summerford and Samulski 2016). For
example, AAV3B uses the human hepatocyte growth factor
(hHGF) receptor, which restricts transduction to primates and
especially to the liver (Vercauteren et al 2016).
Since 2004, AAV vectors have emerged as the leading
candidates for gene therapy in monogenic liver disorders
with the best accepted benefit-risk ratio (Dolgin 2016).
Therefore, the following sections focus on this gene
transfer approach detailing clinical successes and current
limitations.
AAV2 is the most widely studied serotype and was the
first to be vectorized. To generate a recombinant AAV vec-
tor the native Rep and Cap genes are removed and replaced
by a transgene expression cassette with only the flanking
ITRs retained (Fig. 2A). Recombinant virus is produced by
supplying Rep and Cap and necessary adenoviral helper
functions in trans. A major development in AAV vector
technology was the demonstration that recombinant
AAV2 genomes can be cross-packaged, or pseudo-
serotyped, with the capsids from other AAV serotypes
(Rabinowitz et al 2002). This has dramatically broadened
the cell types that can be efficiently targeted with AAV
vectors. For example, pseudo-serotyping a recombinant
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AAV2 vector genome with the AAV8 capsid (designated
AAV2/8) enhances tropism for hepatocytes, particularly in
the mouse (Fig. 2B). AAV vectors bind to target cells via
specific receptors and co-receptors that differ in a capsid-
dependent manner and are taken up by endocytosis or
macropinocytosis, before being trafficked to the nucleus
for capsid uncoating. The uncoated genomes can remain
in the nucleus in single-stranded form, be converted to
double-stranded episomes or undergo genomic integration
(Fig. 3) (Berry and Asokan 2016). Conversion of input
single-stranded genomes to double-stranded transcription-
ally active forms occurs with variable efficiency in differ-
ent cell types. Self-complementary (sc) vectors differ from
single-stranded vectors (ss) in that they contain a self-
complementary transgene cassette that folds back on itself
to form double-stranded DNA thereby bypassing the re-
quirement for second strand synthesis, which is considered
as a rate-limiting step for transgene expression. As a con-
sequence the packaging size of the transgene cassette in
scAAV is reduced by half (McCarty 2008).
Clinical successes of liver-directed AAV-mediated
gene therapy
A rapidly increasing number of publications have reported
proof-of-concept for AAV-based gene therapy in animal
models for various inherited liver disorders including urea
cycle defects, organic acidurias, phenylketonuria, glycogen
storage disease type Ia, long chain fatty acid oxidation disor-
ders, homozygous familial hypercholesterolemia, primary
hyperoxaluria type I and progressive familial intrahepatic cho-
lestasis (Hastie and Samulski 2015; Junge et al 2015).
In parallel, pioneering trials have been conducted since the
2000s, two of which targeted haemophilia B. This disease is
an attractive target for gene therapy as an increase in plasma
factor IX (FIX) of as little as 1% can confer significant phe-
notypic improvement. Haemophilia B is a burden in public
healthcare systems with an annual cost of $300,000 for se-
verely affected patients (Angelis et al 2015).
In 2004, a ssAAV2.ApoE/hAAT.hFIX vector, administered
via the hepatic artery, showed a transient increase of plasma
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expression cassette containing the
promoter, the transgene and
various regulatory elements is
cloned between the 2 ITRs, which
are the only wild type AAV
sequences retained. (b) For vector
synthesis, triple transfection of
three plasmids is performed in a
packaging cell with proviral
plasmid encoding the
recombinant viral genome, a
plasmid containing Rep and Cap
and a helper plasmid.
BPseudotyped^ AAV vectors
contain ITRs from a specific AAV
serotype (usually AAV2) and a
Cap gene encoding viral proteins
(VP1, 2 and 3) from a different
serotype (e.g AAV8) in order to
provide organ-specific
transduction of the recombinant
AAV vector named AAV2/8.
AAV: adeno-associated virus;
Adv: adenovirus; ITR: inverted
terminal repeat
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FIX from <1% to 3–11% over 4 weeks followed by a gradual
decline over 4–8 weeks concomitant with transient asymp-
tomatic rise in transaminases levels (Manno et al 2006), later
recognised as T cell-mediated cytotoxicity (Mingozzi et al
2007).
In 2009, Nathwani et al, injected a scAAV2/8.LP1.hcoFIX
vector via a peripheral intravenous route and elicited a long-
lasting (>5 years) increase of plasma FIX from <1% to 1–8%
(Nienhuis et al 2016). Elevated transaminases occurring 7–
10 weeks post-injection resolved after an oral course of
corticosteroids, but were associated with a decrease of 50–
70% in plasma FIX levels attributable to a cellular immune
response against capsid epitopes (Nathwani et al 2014).
D’Avola et al, recently reported results of a trial of
scAAV2/5.hAAT.hcoPBGD vector in acute intermittent por-
phyria with peripheral intravenous delivery. No vector-related
safety issues were reported and the rate of disease-related
hospitalisation decreased, potentially as a consequence of
closer metabolic follow-up. No change was observed in the
levels of metabolic biomarkers (D’Avola et al 2016). This
Fig. 3 AAV vector uptake, in-cell processing and initiation of the
immune response. Fenestrated endothelium of hepatic sinusoids allows
the AAV vector to freely reach the hepatocyte. Once reaching the target
cell, the vector binds an extracellular receptor and co-receptor specific to
the capsid motifs. After an uptake by endocytosis, the vector is trafficked
in the cytoplasm in early then late endosome. Acidification of the
endosome modifies the capsid conformation. After endosomal escape,
the AAV vector enters the nucleus via the nuclear pore complex. Capsid
uncoating and release of the proviral DNA precede the synthesis of the
2nd strand of DNA. The viral genome then persists either as a non-
integrated single- or double-stranded episome (99%) or (small
percentage) integrates into the host genome (1%). Expression of the
transgene is followed by synthesis of the protein of interest. Cell-
mediated immune responses are initiated by the degradation of capsid
or the transgene product (protein) in the proteasome and presentation at
the surface of the transduced cell via the major histocompatibility
complex I. CD8+ T cells recognise the antigen at the cell surface and
initiate the immune cascade. Neutralising antibodies bind to the vector
in the bloodstream and impair or prevent successful transduction of the
organ target. MHC1: major histocompatibility complex I
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might be explained by a less efficient liver transduction me-
diated by AAV5 relative to AAV8 and a reduced expression of
the episomal transgene compared to the endogenous gene of
interest (Baruteau et al 2017). However, no liver biopsy data
was available to address this assumption.
Preliminary reports from ongoing clinical trials have con-
firmed Nathwani’s promising results for haemophilia B. After a
single intravenous injection of AAV vectors with different cap-
sids encoding the FIX gene or its Padua FIX variant, which
contains a gain-of-function mutation, reported stabilised plasma
FIX levels have ranged from 3 to 8% in the AMT-060 trial
sponsored by Uniqure (Miesbach et al 2016) and the DTX-101
sponsored by Dimension Therapeutics (http://dimensiontx.com)
to 20–44% in the high-dose cohort of the BAX 335 trial spon-
sored by Shire (Monahan et al 2015) and in the SPK-9001 trial
sponsored by Spark Therapeutics/Pfizer (George et al 2016). In a
haemophilia A gene therapy trial, BioMarin reported plasma fac-
tor VIII (FVIII) from 4 to 60% in the high-dose group of the
BMN 270 trial (Pasi et al 2016) (Table 1). Importantly, endoge-
nous FVIII is primarily secreted by endothelial cells (Fahs et al
2014). All the AAV-based trials have so far involved only adult
patients, who had an undetectable baseline titre of neutralising
antibodies to the capsid (usually accepted cut-off of 1/5 serum
dilution). Monogenic liver disorders in AAV-based gene therapy
development pipelines of pharmaceutical companies include
OTCD, glycogen storage disease type Ia, citrullinemia type I,
phenylketonuria, Wilson disease, methylmalonic acideamia and
Crigler-Najjar syndrome (Kattenhorn et al 2016).
Current challenges
Insertional mutagenesis
Despite more than 170 AAV-based human trials approved,
ongoing or completed (http://www.abedia.com/wiley/
(accessed 2017 Jan 06)), no tumorigenic events have been
reported so far. AAV vector genome mainly persists as
episome in the transduced cell with a relatively low
proportion of vector genomes undergoing integration
preferentially in transcriptionally active genes, damaged
DNA or enriched CpG islands (McCarty et al 2004).
Experiments in neonatal mice have identified an increased risk
of hepatocellular carcinoma (HCC) after systemic injection.
This risk increased with the enhancer/promoter activity, youn-
ger age at time of injection and vector dose (Donsante et al
2007; Chandler et al 2015; Chandler et al 2017). Analysis of
integration sites identified a rodent-specific hotspot in the
Rian locus. Integration studies from human trials have not
shown such hotspots, but rather a genome wide integration
pattern involving neither HCC-related genes nor the human
Rian homologue, Dlk1-Dio3 (Kaeppel et al 2013; Gil-Farina
and Schmidt 2016).
Controversies remain regarding the possible insertional
mutagenic effects of wild type AAV. Detection of a clonal
expansion of wild type AAV2 sequences in 11/193 HCCs
within HCC-related genes (Nault et al 2015) initiated a pas-
sionate and unresolved debate about Bdriver^ or Bpassenger^
cancer-related genetic modifications (Berns et al 2015;
Buning and Schmidt 2015). The cumulative safety experience
with the rapidly growing number of AAV-based trials
targeting the human liver, combined with the low rate of
HCC-associated AAV integrations despite the high seroprev-
alence of wild type AAV in the human population (e.g. >50%
for AAV2) (Thwaite et al 2015) are consistent with a
favourable safety profile of AAV vectors. Nevertheless the
findings of Nault et al warrant further studies and mandate
close monitoring in ongoing human trials.
Immune response
After vector delivery, non-specific innate immunity trig-
gers both type I interferon signalling involved in trans-
gene silencing (Suzuki et al 2013) and the release of pro-
inflammatory cytokines (Jayandharan et al 2011). Highly-
specific and long-lasting adaptive immunity generates B-
and T-cell responses against the capsid and/or the trans-
gene product (Fig. 3). Neutralising antibodies against the
capsid, even at low titers, inhibit transduction after sys-
temic delivery (Jiang et al, 2006a, b). This barrier is of
substantial concern to gene therapy development and the
ongoing liver-directed trials are recruiting only seronega-
tive patients without neutralising antibodies against the
AAV capsid. This narrows the target population as the
seroprevalence against liver-specific AAV serotypes
ranges from 20 to 30% for AAV5, 6 and 8 to 50–60%
for AAV2 (Louis Jeune et al 2013). Cross-reactivity be-
tween serotypes is commonly >50% (Boutin et al 2010).
This seroprevalence varies depending on geographic ori-
gin (Calcedo et al 2009) and age. Neonates receive ma-
ternal antibodies by transplacental transfer and acquired
with maternal milk, which are lost over the first months
of life. Thereafter, seroprevalence remains negligible until
3 years of age after which the seroconversion rate pro-
gressively increases until adulthood (Calcedo et al 2011;
Li et al 2012).
Human CD8+ T-cell mediated immune responses are in-
volved in AAV hepatotoxicity and were initially encountered
during the first haemophilia B trial (Manno et al 2006). Capsid
epitopes, presented via the major histocompatibility complex I
(MHC1), were shown to drive expansion of a pre-existing
pool of CD8+ memory T cells acquired during a previous
co-infection of wild type AAV and helper virus (adenovirus
or herpes virus for example). This response was dose-
dependent (Mingozzi and High 2013) and could be stimulated
by alternate capsids (Mingozzi et al 2007).
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Hepatic tolerogenic properties involve the proliferation of a
specific T cell subset, CD4+CD25+FoxP3+ Treg cells (Cooper
et al 2009) interacting with Kupffer cells (Breous et al 2009).
Expansion of these cells suppresses cytotoxic immunity
against AAV-transduced hepatocytes and induces
immunotolerance, e.g. after neonatal injection (Shi et al
2013). Regulatory tolerance requires continuous antigen pre-
sentation and has been successfully induced with transgenic
proteins (Shi et al 2013; Perrin et al 2016). In contrast, capsid
proteins are rapidly eliminated in the proteasome (Berry and
Asokan 2016) and therefore very unlikely to induce tolerance.
Various approaches aim to overcome these unwanted
immune responses in order either to treat seropositive
patients or to prevent sensitisation against the AAV cap-
sid, which would allow reinjection in the future. Capsid
modification targeting specific epitopes can evade host
immunity (Tseng and Agbandje-McKenna 2014). Any
strategy optimising the transduction of the target organ
such as optimised expression cassette design, or capsid
modifications will in turn decrease the amount of vector
required for a similar effect. The decrease in vector
dose wil l further reduce the immune response
(Mingozzi and High 2011). Various protocols involving
transient immunosuppression have been proposed in
large animal models and humans. These include plasma-
pheresis (Monteilhet et al 2011; Chicoine et al 2014),
monoclonal antiCD20 antibody (rituximab) (Mingozzi
et al 2013; Corti et al 2014), non-depleting antiCD4
antibody (McIntosh et al 2012), sirolimus (Corti et al
2014), cyclosporine A (McIntosh et al 2012; Mingozzi
et al 2012), tacrolimus with mycophenolate mofetil
(Chicoine et al 2014), proteasome inhibitors, e.g.
bortezomib (Monahan et al 2010) and corticosteroids
(Flanigan et al 2013; Chicoine et al 2014; Nathwani
et al 2014). One currently controversial strategy to blunt
anti-capsid immune responses, is to co-inject Bfull^
AAV vectors and Bempty^ capsids as decoys, in an at-
tempt to competitively bind existing antibodies (Tse
et al 2015).
Optimised targeting
The ideal AAV vector would exclusively transduce the
desired target cells. This would limit unwanted immune
responses, avoid ectopic transgene expression and fur-
ther reduce the already low risk of germline transmis-
sion. Extensive capsid-focused research based on high-
throughput in vitro and in vivo screening of Blibraries^
of new capsid variants is ongoing in order to optimise
vectors for specific applications. These Baccelerated
evolution^ libraries are generated using strategies such
as error-prone PCR (Kotterman and Schaffer 2014;
Deverman et al 2016) and Bcapsid shuffling^ with ran-
dom cut-paste sequences of wild type cap genes (Kay
2011; Louis Jeune et al 2013; Choudhury et al 2016).
This approach is paying off by generating re-engineered
AAV variants with increased transduction efficiency in
primary human hepatocytes (Lisowski et al 2014).
Germline transmission
The risk for this phenomenon is difficult to quantify.
Insertion of AAV sequences into the genome of a gam-
ete could potentially interfere with normal foetal devel-
opment or promote tumorigenicity in the progeny. So
far adult patients enrolled in AAV trials with systemic
delivery have been required to use contraception. Vector
sequences have been detected transiently in semen of
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Fig. 4 Species-related differences in transduction of the hepatic lobule by AAV vector compared with metabolic zonation for ammonia clearance:
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treated patients in AAV2 (Manno et al 2006) or AAV8
(Nathwani et al 2014) trials with the latest clearance of
the vector observed at 12 weeks post-injection, quicker
in younger men, but not in an AAV5 trial (D’Avola
et al 2016). Vector was observed in seminal fluid but
not in motile sperm and spermatogonia aligned with
previous studies (Arruda et al 2001; Couto et al 2004).
Suboptimal animal models
The following examples demonstrate why animal experiments
provide limited value for predicting effects in human trials:
– T-cell mediated cytotoxicity observed in the first
haemophilia B trial was not predicted by experiments in
mice, dogs or non-human primates (Pien et al 2009).
Unlike research animals, humans are exposed to wild
type AAV infections generating anti-AAV memory T
cells, which are reactivated at the time of vector exposure
(Mingozzi et al 2007).
– An over 80% rate of HCC was observed in a mouse
model of methylmalonic acidaemia injected neonatally
with AAV2/8. Integration occurred in the Rian hotspot,
a rodent-specific locus absent in other vertebrate genomes
(Chandler et al 2015).
– The patterns of liver transgene expression in the hepatic
lobule varies among different species. For example, using
the AAV8 capsid, transgene expression is predominantly
pericentral in mice and dogs and periportal in non-human
primates (Fig. 4) (Bell et al 2011). This is of particular
importance for liver diseases where metabolic zonation
underpins that certain metabolic functions occur predom-
inantly in certain areas of the liver lobule, which is the
functional unit of the liver. For example, the urea cycle
activity mostly takes place in periportal hepatocytes
(Gebhardt and Matz-Soja 2014). To achieve adequate
control of severe hyperammonaemia in the OTCDmouse
model, therefore, requires a much higher than expected
dose of AAV2/8 vector carrying OTC transgene, which
might be explained by the non-physiological pattern of
liver transduction (Cunningham et al 2011). Thus, it is
difficult to reliably extrapolate vector doses for human
translation from studies in mice in liver diseases with
metabolic zonation like OTCD.
– AAV2/8 vectors are capable of transducing 100% hepa-
tocytes in adult mice (Cunningham et al 2008), but data
from human trials in haemophilia B have shown an in-
crease in plasma FIX only 2 to 8% (Nienhuis et al 2016),
suggesting much less efficient AAV2/8-mediated hepato-
cyte transduction in humans. Interestingly, most studies in
a chimeric FRG (Fah−/−/Rag2−/−/Il2rg−/−) mouse-
human liver model (Lisowski et al 2014; Wang et al
2015; Vercauteren et al 2016) showed that AAV3B and
AAV3B-derived vectors (AAV3-ST, AAV-LK03) are able
to transduce human hepatocytes approximately 10 times
more efficiently than AAV2/8 whilst transduction of mu-
rine hepatocytes is minimal (Lisowski et al 2014).
The FRG mouse has a combination of tyrosinaemia type I
and immunodeficiency phenotypes and is an attractive model
to study human hepatocytes in vivo with the intention of over-
coming limitations due to species-specificity (Azuma et al
2007). Human Fah+/+ hepatocytes have a selective growth
advantage relative to the Fah-deficient native mouse hepato-
cytes allowing human cell engraftment up to 90% of the liver
mass (Azuma et al 2007). Moreover, this model can address
disease-specific questions if engrafted with hepatocytes from
patients with liver specific disorders. Recently, the even more
complex FRGN (Fah−/−/Rag2−/−/Il2rg−/−/NOD) mouse
model has been described in which FRG mice, developed in
a non-obese diabetic (NOD) mouse strain, are simultaneously
co-transplanted with human hepatocytes and human
haematopoietic stem cells (Wilson et al 2014).
Limited capacity of AAV vectors
The single-stranded AAV vector can accommodate a trans-
gene cassette of approximately 4.6 to 5 kb (Hirsch et al
2016). This capacity is reduced by half (2.3 kb) in self-
complementary (i.e double-stranded) vectors. This is a major
limitation compared to non-viral or other common viral vec-
tors like lentiviral/retroviral vectors (up to at least 14 kb
(Counsell et al 2017)) or helper-dependent adenoviruses (up
to at least 38.9 kb (Suzuki et al 2011)). To deliver oversized
transgenes, several approaches have been developed.
Designing mini-promoters or mini-genes of interest can be
successful (Yan et al 2015). Alternatively, dual AAV co-
transduction has been successfully tested either with split
AAV or fragment AAV (Hirsch et al 2016). Split AAVs use
the inherent tendency for intermolecular genome association
observed with AAV genomes via either homologous recom-
bination (HR) or non-homologous end joining (NHEJ) to pro-
duce concatemers. The overlapping approach uses vectors A
and B, which display a homology sequence to promote inter-
molecular homologous recombination (Duan et al 2001; Koo
et al 2014). In the trans-splicing approach, two splice sites in 3′
cDNA of vector A and 5′ cDNA of vector B are recognised in
concatemerized provirus to generate the single DNAmolecule
of the oversized gene of interest (Duan et al 2001). A combi-
nation of the two approaches is known as the hybrid trans-
splicing technique (Trapani et al 2014). In fragment AAV, the
transgene is not entirely encapsidated but only fragments of
different size, which can recombine on overlapping regions
(Hirsch et al 2016). A limitation common to these approaches
is reduced functional transduction efficiency.
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Limited manufacturing capability
For the last couple of years, the rise in demand for good-
manufacturing practice (GMP) AAV vectors for preclinical
and clinical studies has created a bottleneck, delaying a num-
ber of projects. The industry is progressively taking up the
gauntlet and developing improved and innovative methods
for vector production in larger bioreactors with optimised re-
agents, purification techniques and packaging cell lines
(Clement and Grieger 2016; Grieger et al 2016).
Gene therapy requires an innovative economic model
for success in modern healthcare
Patients with inherited metabolic disorders individually im-
pose a much heavier financial burden on the healthcare system
compared to the average person. For example, the lifetime
cost for methylmalonic/propionic acidaemias and Gaucher
disease is $1.5 and 5 million, respectively (Li et al 2015;
Orkin and Reilly 2016). Gene therapy has the potential to
achieve substantial savings. For example, a haemophilia B
trial has shown that single injection of the gene therapy prod-
uct in a cohort of ten patients can save more than $2.5 million
over three years for the healthcare system in the UK
(Nathwani et al 2014).
It is likely that to recover the investment in product devel-
opment, companies will need pricing gene therapy treatments
ambitiously when their products reach market. However, the
cost of treatment will need to be affordable for public
healthcare systems. The first gene therapy product approved
by the European Medicines Agency (EMA), Glybera®, is
marketed by Uniqure. This drug has been in development
for 8 years, with the initial developer going bankrupt and a
currently proposed market cost of $1.2 million per patient
(Bryant et al 2013). GlaxoSmithKline‘s Strimvelis® is the
second gene therapy product to reach the market and was
approved by the EMA in 2016. This gene therapy product,
which targets ADA-SCID has been in development for over
16 years and the proposed cost is $665,000 per patient
(Hoggatt 2016; Schimmer and Breazzano 2016).
Over the last 20 years, greater than $4.3 billion have been
spent on development of gene therapy technology and return
on this investment is still awaited (Ledley et al 2014).
Although most of the gene therapy programmes remain in
the early stages of development, healthcare economists are
generating models to cost treatments, which might provide
lifelong cures. A pay-for-performance system has been pro-
posed with yearly-capped annuity paid to the pharmaceutical
company if criteria of a metabolic control of the disease aremet
(Touchot and Flume 2015). These criteria might reflect cost-
effectiveness and not only cost-saving. This approach values
the gain in quality of life estimated by quality-adjusted life
years (QALY) analysis, which includes many parameters such
as lifespan and ability to work (Orkin and Reilly 2016).
Vouchers systems with longer financial incentives might be
another option (Schimmer and Breazzano 2016).
In parallel, the regulatory framework is evolving with the
progress of technology and the increasing experience being
gathered from human trials . The Food and Drug
Administration (FDA) and the EMA have published recom-
mendations for gene therapy products (Narayanan et al 2014).
The need for shorter and less expensive paths to clinical trials
and conditional approval relying more on human data for
safety and efficacy has now been recognised, as exemplified
by the FDA’s Breakthrough Therapies programme and the
EMA’s Adaptive Pathways and Priority Medicines (PRIME)
schemes which were launched in 2012, 2014 and 2016, re-
spectively (Mullard 2016). These more flexible pathways will
need to be agreed by government funding bodies (Macaulay
2015).
Considerations for paediatric application
Paediatric administration of gene therapy has several theoret-
ical advantages (McKay et al 2011). These include prevention
of early death or irreversible neurological sequellae, transduc-
tion of stem/progenitor cells and possible avoidance of im-
mune response as neonates have an immature immune system,
while infants and children have lower rates of pre-existing
anti-AAV immunity. The potential for even earlier gene ther-
apy intervention has been explored in late gestation foetal
macaques by intrahepatic injection of scAAV2/8 and
scAAV2/5 vectors. Plasma human FIX levels of 8–112%were
observed during a median follow-up period of 14 months
without evidence hotspot integration and HCC (Mattar et al
2011).
There is a theoretical risk, however, of increased tumorige-
nicity in the developing liver as observed in experiments per-
formed in neonatal mice (Donsante et al 2007; Chandler et al
2015). A further challenge in the paediatric liver is the likely
progressive loss of vector genomes over time in concert with
hepatocellular proliferation. More than 90% of the AAV-
delivered transgene cassettes exists as non-integrated epi-
somes (Cunningham et al 2008). The human liver weight
doubles at 4 months, 16 months, 6 years and 12 years of
age, which means that the adult liver is 16 times heavier than
the neonatal liver (Coppoletta and Wolbach 1933; Sunderman
and Boerner 1949). Therefore, it is unlikely that a neonatal
injection will be sufficient to provide lifelong correction of the
phenotype in metabolic liver diseases, with reinjection during
the phase of rapid liver growth likely to be necessary.
An alternative approach to reinjection could be the use of
integrating vectors and or locus-specific genome engineering.
Sangamo Therapeutics Inc. is developing tools for transgene
integration into the albumin locus and uses zinc finger
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nucleases coupled with AAV technology. Other genome
editing tools have been successfully tested with AAV vectors
in a neonatal OTC deficiency mouse model. In these experi-
ments, two AAV vectors were injected simultaneously, one of
which encoded the transgene and the other the enzymatic sys-
tem for integration or site specific cutting by Piggybac
transposase (Cunningham et al 2015) and CRISPR-Cas9
(Yang et al 2016), respectively.
Muscle-directed gene therapy for liver monogenic
disorders
Muscle-directed gene therapy has been developed for liver
monogenic disorders with secreted protein such as
haemophilia A and B and α1-antitrypsin deficiency.
Intramuscular injections might circumvent some caveats ob-
served with systemic injection, the common route of delivery
for liver-targeted gene therapy: limited biodistribution with
reduced risk of germline transmission, minimal exposure to
circulating neutralising antibodies, reduced dose of vector for
a similar effect.
A proof of concept using AAV2 vectors in mice (Herzog
et al 1997) and dogs (Herzog et al 1999) affected by
haemophilia B paved the way for a clinical trial (Kay et al
2000; Manno et al 2003), which showed a safe profile with
long-standing expression in some patients (Jiang et al, 2006a,
b; Buchlis et al 2012) but only a mild increase in plasma factor
IX around 1% (Manno et al 2003). Depending on the dose
considered, dozens to hundreds of intramuscular injections are
necessary, whichmakes this route particularly impractical. For
instance, Manno et al administered between 10 to 90 injec-
tions per patients in lower limbs (Manno et al 2003). Similarly,
a proof of concept in mice with haemophilia A has been re-
ported (Mah et al 2003).
Three AAV-mediated clinical trials have been conducted
for α1-antitrypsin deficiency. In this disorder, a plasma level
of wild-type (M) α1-antitrypsin above 11 μM is considered
reducing the risk of developing emphysema. A first trial based
on an AAV2 capsid showed an acceptable safety profile with
mild local reactions at the site of intramuscular injection (red-
ness, tenderness, bruising) and a seroconversion against
AAV2. Unfortunately, only one out of 12 patients demonstrat-
ed a minimal increase of plasma M α1-antitrypsin at 82 nM
(Flotte et al 2004; Brantly et al 2006). Two other trials (phase I
then phase II) were conducted with a vector based on AAV1
capsid known for its better muscle transduction compared to
AAV2 (Flotte et al 2011). In both trials, minor side effects and
a seroconversion against AAV1 were observed (Brantly et al
2009; Flotte et al 2011). A moderate infiltration of reactive T
lymphocytes in muscle biopsies was noticed (Flotte et al
2011). Plasma levels of M α1-antitrypsin were still mild, al-
though improving in the latest trial due to higher doses
injected (412 to 694 nM in the highest dose group) but far
from the targeted protective level of 11 μM (Flotte et al 2011).
Conclusion
Over the last decade, major discoveries in the understanding of
viral vector biology have generated promising results in
pioneering clinical trials for haemophilia B using AAV vectors.
This has paved the way for a wider development of AAV-
mediated gene therapy for monogenic liver disorders. Although
several clinical, manufacturing and economic challenges remain,
this approach to treatment for severely debilitating diseases gen-
erated widespread enthusiasm shared by clinicians, researchers
and investors alike. Gene transfer technologies are reaching an
exciting threshold of efficacy and promise to revolutionise the
management of many currently untreatable diseases.
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